 |
|
|
| |
Every-8-weeks injectable cabotegravir and rilpivirine is superior to daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir in adolescents living with HIV in sub-Saharan Africa: LATA 96-week results
|
| |
| |
Mutsa BWAKURA DANGAREMBIZI, Zimbabwe
IAS 2026 Rio, Brazil
|
| |
|
|
|
|
|
